Characteristics of Pulmonary Vein Enlargement in Non-Valvular Atrial Fibrillation Patients with Stroke

Jung Myung Lee,1* Jong-Youn Kim,1* Jaemin Shim,1 Jae-Sun Uhm,1 Young Jin Kim,2 Hye-Jeong Lee,2 Hui-Nam Pak,1 Moon-Hyoung Lee,1 and Boyoung Joung1

1Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul; 2Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea.

Received: August 21, 2013  
Revised: January 7, 2014  
Accepted: February 10, 2014

Corresponding author: Dr. Boyoung Joung, Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-2228-8460, Fax: 82-2-393-2041  
E-mail: cby6908@yuhs.ac

*Jung Myung Lee and Jong-Youn Kim contributed equally to this work.

- The authors have no financial conflicts of interest.

© Copyright:  
Yonsei University College of Medicine 2014  
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose: The association between pulmonary vein (PV) dilatation and stroke in non-valvular atrial fibrillation (AF) patients remains unknown. Materials and Methods: We examined the left atrium (LA) and PV in control (n=138) and non-valvular AF patients without (AF group, n=138) and with non-hemorrhagic stroke (AF with stroke group, n=138) using computed tomography. Results: The LA, LA appendage (LAA), and all PVs were larger in the AF than control patients. The orifice areas of the LAA (5.6±2.2 cm\(^2\) vs. 4.7±1.7 cm\(^2\), \(p<0.001\)), left superior PV (3.8±1.5 cm\(^2\) vs. 3.4±1.2 cm\(^2\), \(p=0.019\)), and inferior PV (2.3±1.0 cm\(^2\) vs. 1.8±0.7 cm\(^2\), \(p<0.001\)) were larger in the AF with stroke than in the AF only group. However, right PVs were not different between the two groups. In a multivariate analysis, the orifice areas of the left superior PV [odds ratio (OR) 1.25, 95% confidence interval (CI) 1.03–1.51, \(p=0.02\)], left inferior PV (OR 1.97, 95% CI 1.41–2.75, \(p<0.001\)), and LAA (OR 1.30, 95% CI 1.13–1.50, \(p<0.001\)) were independent predictors of stroke. Conclusion: Compared to the right PVs, the left PVs and LAA exhibited more significant enlargement in patients with AF and stroke than in patients with AF only. This finding suggests that the remodeling of left-sided LA structures might be related to stroke.

Key Words: Atrial fibrillation, stroke, pulmonary veins, atrial appendage, multidetector computed tomography

INTRODUCTION

Atrial fibrillation (AF) is the most common cardiac abnormality associated with ischemic stroke.\(^1\)\(^2\) Cardiogenic cerebral embolism is responsible for approximately 20% of all ischemic strokes. A number of other clinical features also increase the risk of stroke in patients with AF, including age, congestive heart failure (CHF), hypertension, diabetes, and prior thromboembolism. Left ventricular dysfunction, left atrial (LA) size, mitral annular calcification, spontaneous echo contrast, and LA thrombus on echocardiography also increase the thromboembolic risk.\(^3\)

Pulmonary veins (PVs) are important structures for the generation and maintenance of AF and are the main targets of radiofrequency catheter ablation.\(^4\)\(^5\) In a pre-
vious report, PVs in patients with AF showed characteristic electrophysiological remodeling, including a lower mean voltage, slower conduction, and higher prevalence of complex signals. The positive relationship between LA size and AF is well recognized. Herweg, et al demonstrated that AF patients with hypertension had more prominent PV dilatation than patients in the control group, and patients with persistent AF had more increased PV ostial diameter than patients with paroxysmal AF. It is likely that impaired left ventricular diastolic function is associated with a stretch-induced PV arrhythmia. PV dilatation may be the crosslink between LA enlargement and AF. However, despite the important role of PVs in the pathophysiology of AF, the association between PV remodeling and stroke in AF patients is poorly understood. This problem might be due to the limitations of current diagnostic tools. Notwithstanding, the latest multidetector computed tomography (MDCT) technology permits cardiac scanning with high spatial and temporal resolution and provides precise measurements (less than 1 mm) and three-dimensional information. Specifically, this technology can be used to obtain reliable information on the diameter, cross-sectional area, and estimated volume of the LA and LA appendage (LAA).

We hypothesized that specific features of PVs might be related to a higher stroke risk in patients with non-valvular AF. Accordingly, we analyzed the three-dimensional (3D) geometry and dimensions of LA structures, including PVs and LAA, using MDCT in AF and control patients. The purpose of this study was to determine the characteristics of remodeling of the LA and PVs in AF patients with stroke, which is different than that in patients without stroke. Finally, we also sought to determine if specific patterns and variants of PV anatomy might be predictive of stroke in non-valvular AF.

MATERIALS AND METHODS

Patient sample
The study protocol was approved by the Institutional Review Board of Severance Hospital, Seoul, Korea, and complied with the tenets of the Declaration of Helsinki. All patients provided written informed consent. From February 2008 to February 2011, 138 consecutive, non-hemorrhagic stroke with non-valvular AF patients who underwent cardiac MDCT were enrolled (AF with stroke group). The AF group included 138 age-sex matched non-valvular AF patients without stroke who underwent MDCT at the same period. The control group included 138 age-sex matched patients without AF and stroke who underwent concurrent MDCT. Similar to a previous study, only patients with non-valvular AF who were not taking anticoagulants at the time of their stroke, or at the time of cardiac MDCT for patients without a history of stroke, were included.

The CHADS2 (Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack) and CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack, vascular disease, Age >65, female) scores of each patient were presented with and without points of stroke. CHF was defined as clinical heart failure (stage C or D) according to the 2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Hypertension was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg at two or more visits or past medical history of hypertension. AF was classified as paroxysmal AF when an episode of AF was self-terminating within 7 days and persistent AF when an AF episode either lasted longer than 7 days or required termination by cardioversion, either with drugs or by direct current cardioversion.

Cardiac MDCT
Contrast-enhanced cardiac CT scans were performed using a 64-slice MDCT (Somatom Sensation 64, Siemens Medical Solutions, Forchheim, Germany). A bolus of 60–80 mL iopamidol (Iopamiro 370, Bracco, Italy) was injected into the antecubital vein at a flow rate of 5 mL/s, which was followed by a 50-mL saline-chasing bolus at 5 mL/s. The start delay was defined as bolus tracking in the ascending aorta, and the scan was automatically initiated 5 seconds after reaching a threshold of 140 Hounsfield units. Scanning was performed using the following parameters: retrospective ECG-gated acquisitions, 80–120 kVp, 500–700 mAs depending on patient size, and 64×0.6 mm slice collimation. Scans were performed from the tracheal bifurcation to the diaphragm. The field of view was adjusted according to the size of the heart. Cardiac CT scans were reconstructed at the end-systolic and mid-diastolic phases using a slice thickness of 0.75 mm, an increment interval of 0.5 mm, and a medium-smooth convolution kernel of B36f. We used end-systolic CT images for this study.

Two radiologists (with four and eight years of experience
was used as a surrogate value for this area. PV dimensions change significantly between end systole and end diastole, and the ostia of the superior PVs are most vulnerable to dimensional inaccuracies. To overcome this problem, we used ECG-gated cardiac CT to provide a more precise method of PV dimensional measurement than non-gated techniques. LAA morphology was evaluated using the method described by Di Biase, et al. Thrombus was defined as a filling defect with an oval or convex shape, and blood stasis was defined as a typical triangular filling defect at the ventral side of the LAA, which appeared as fluid-fluid levels.

Statistical analysis

Normally distributed continuous variables were reported as mean±SD and compared with Student’s t-test. Categorical variables were reported as a percentage and compared with either Pearson’s chi square test or Fisher’s exact test. A multivariable logistic model was used to identify significant predictors of stroke. All potential confounders were entered into the model on the basis of known clinical relevance or significant associations observed in the univariate analysis. A receiver operating characteristic (ROC) curve was computed for the completed prediction model, and we chose a
probability threshold for predicting the likelihood of stroke. The Statistical Package for the Social Sciences (SPSS, SPSS Inc., Chicago, IL, USA) was used for all statistical evaluations. All $p$-values $<0.05$ were considered statistically significant.

RESULTS

Patient characteristics

Patient demographic and clinical characteristics are presented in Table 1. Compared to age- and sex-matched AF patients without stroke, AF patients with stroke had a higher prevalence of persistent AF (34% vs. 59%, $p<0.001$) and hypertension (56% vs. 76%, $p=0.001$), as well as higher CHADS$_2$ (1.4±1.1 vs. 1.7±0.9, $p=0.006$) and CHA$_2$DS$_2$-VASc scores (1.8±1.2 vs. 2.1±1.1, $p=0.014$).

Remodeling of the LA and LAA in AF patients with stroke

Table 2 shows a comparison of the LA, LAA, and PV features measured by MDCT between patient groups. The mean LA volumes for the control, AF, and AF with stroke groups were 101±25 cm$^3$, 143±43 cm$^3$, and 163±53 cm$^3$ ($p<0.001$), respectively. The LA dimensions measured by transesophageal echocardiography also showed progressive enlargement from control group to AF and stroke group. Interestingly, AF patients with stroke (5.6±2.2 cm$^2$) had larger LAA orifice areas than the control (3.5±1.3 cm$^2$, $p<0.001$) and AF only patients (4.7±1.7 cm$^2$, $p<0.001$). The percentage of volume ratio between LAA and LA in the AF with stroke group were larger than that of AF group (10.6±4.0% vs. 9.2±3.3%, $p=0.011$). These findings suggest progressive LA remodeling from control to AF with stroke groups.

Differences in enlargement of the left and right PVs in AF patients with stroke

Orifice areas of the LAA were larger in the AF group (4.7±1.7 cm$^2$) than the control group (3.5±1.3 cm$^2$, $p<0.001$). The AF group also had larger orifice areas of all PVs than control patients. The orifice areas of the LAA (5.6±2.2 cm$^2$ vs. 4.7±1.7 cm$^2$, $p<0.001$), left superior PV (3.8±1.5 cm$^2$ vs. 3.4±1.2 cm$^2$, $p=0.019$), and inferior PV (2.3±1.0 cm$^2$ vs. 1.8±0.7 cm$^2$, $p<0.001$) were larger in the AF with stroke group than the AF group. However, the orifice areas of the right PVs were not different between the AF only and the AF with stroke groups (Table 2, Fig. 2). We could not identify any differences in the LAA morphology between the three groups. There were no differences in PV type between the three groups.

Table 1. Patient Demographic and Clinical Characteristics

|                      | Control (n=138) | $p$ value* | AF (n=138) | $p$ value† | AF with stroke (n=138) |
|----------------------|----------------|------------|------------|------------|------------------------|
| Age, yrs             | 66±9           | 1.0        | 65±8       | 0.87       | 66±8                   |
| Female, n            | 45 (33%)       | 0.514      | 40 (29%)   | 0.436      | 46 (33%)               |
| Persistent AF, n     | N/A            |            | 47 (34%)   | <0.001     | 81 (59%)               |
| Comorbidities, n     |                |            |            |            |                        |
| CHF                  | 4 (3%)         | 0.356      | 7 (5%)     | 0.791      | 8 (6%)                 |
| Hypertension         | 77 (56%)       | 1.0        | 77 (56%)   | 0.001      | 105 (76%)              |
| Age >75 yrs          | 26 (19%)       | 0.04       | 14 (10%)   | 0.839      | 13 (9%)                |
| Diabetes mellitus    | 31 (23%)       | 0.555      | 27 (20%)   | 0.119      | 38 (28%)               |
| Dyslipidemia         | 39 (28%)       | 0.123      | 28 (20%)   | 0.882      | 29 (21%)               |
| CHADS$_2$           | 1.35±0.95      | 1.0        | 1.36±1.05  | 0.006      | 1.72±0.88              |
| CHA$_2$DS$_2$-VASc   | 1.35±0.95      | 1.0        | 1.36±1.05  | <0.001     | 3.72±0.88              |
| BMI                  | 24±0.29        | 0.595      | 24.5±2.8   | 0.213      | 23.8±3.1               |
| LVEF, %              | 68.1±5.5       | 0.003      | 63.3±7.8   | 1.0        | 62.8±11.0              |
| Aspirin use, n       | 55 (40%)       | <0.001     | 97 (70%)   | 0.517      | 92 (67%)               |

AF, atrial fibrillation; CHF, congestive heart failure; BMI, body mass index; LVEF, left ventricular ejection fraction; N/A, not applicable.

* $p$-value of control vs. AF groups.
† $p$-value of AF vs. AF with stroke groups.
‡ CHADS$_2$ and CHA$_2$DS$_2$-VASc scores were calculated excluding points of stroke for stroke group.
Thrombus or blood stasis of LAA and left side PV enlargement

For all 276 patients with AF, thrombus or blood stasis were observed in 20 (7.2%) and 42 (15.2%) patients, respectively. While thrombus or blood stasis were observed in 51 (37.0%) AF patients with stroke, these complications were found in only 11 (8.0%) patients in the AF group (*p<0.001). Table 3 shows a comparison of the clinical features and LA remodeling between patients with and without thrombus or blood stasis of the LAA. Patients with thrombus or blood stasis were older (67.3±7.2 years vs. 65.1±7.6 years, *p=0.04), had a higher prevalence of persistent AF (82% vs. 36%, *p<0.001), higher CHADS2 scores (1.8±0.8 vs. 1.5±1.0, *p=0.006), and higher CHA2DS2-VASc scores (2.3±1.0 vs. 1.8±1.2, *p<0.004) than those without thrombus or blood stasis. LA volume (190.2±52.8 cm³ vs. 141.0±41.4 cm³, *p<0.001), LAA

Table 2. Comparisons of Pulmonary Vein Features Measured by MDCT

|                      | Control (n=138) | *p value* | AF (n=138)  | *p value† | AF with stroke (n=138) |
|----------------------|----------------|-----------|-------------|-----------|------------------------|
| **Volumes**          |                |           |             |           |                        |
| LA volume, cm³       | 101±25         | <0.001    | 143±43      | 0.002     | 163±53                 |
| LAA volume, cm³      | 8.7±3.4        | <0.001    | 12.9±5.4    | <0.001    | 17.0±8.8               |
| LAA/LA volume, %     | 8.7±2.6        | 0.756     | 9.2±3.3     | 0.011     | 10.6±4.0               |
| **LA dimensions (TTE)** |              |           |             |           |                        |
| Anterior-posterior, mm | 36.2±5.6      | <0.001    | 41.4±5.9    | <0.001    | 46.2±7.4               |
| Medial-lateral, mm    | 37.8±4.3       | 0.005     | 48.4±7.5    | 0.011     | 58.2±6.6               |
| Superior-inferior, mm | 50.4±4.4       | 0.004     | 63.0±9.3    | 0.034     | 72.5±7.4               |
| **Orifice area, cm²** |                |           |             |           |                        |
| LAA                  | 3.5±1.3        | <0.001    | 4.7±1.7     | <0.001    | 5.6±2.2                |
| LSPV                 | 2.7±0.9        | <0.001    | 3.4±1.2     | 0.019     | 3.8±1.5                |
| LIPV                 | 1.6±0.5        | 0.012     | 1.8±0.7     | <0.001    | 2.3±1.0                |
| RSPV                 | 3.1±1.1        | <0.001    | 4.0±1.3     | 0.245     | 3.7±1.4                |
| RIPV                 | 2.3±0.8        | <0.001    | 2.8±1.0     | 0.98      | 2.7±1.1                |
| **LAA morphology**   |                |           |             |           |                        |
| Chicken-wing type    | 70 (51%)       | 0.398     | 77 (56%)    | 0.464     | 83 (60%)               |
| **PV morphology**    |                |           |             |           |                        |
| Common LPV           | 8 (6%)         | 0.802     | 9 (7%)      | 0.812     | 10 (7%)                |
| Accessory RPV        | 20 (15%)       | 0.333     | 26 (19%)    | 0.333     | 20 (15%)               |

LA, left atrium; LAA, left atrial appendage; TTE, transthoracic echocardiography; AF, atrial fibrillation; MDCT, multidetector computed tomography; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; RSPV, right superior pulmonary vein; RIPV, right inferior pulmonary vein; LPV, left pulmonary vein; RPV, right pulmonary vein.

*p-value of control vs. AF groups.
†p-value of AF vs. AF with stroke groups.

Fig. 2. Comparison of LA volume (A) and orifice area of the LAA and PVs (B) between the three patient groups. LA, left atrium; LAA, left atrial appendage; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; RSPV, right superior pulmonary vein; RIPV, right inferior pulmonary vein.

* p<0.005.
Table 3. Thrombus or Blood Stasis of the LAA and Left PV Enlargement in Patients with AF

|                        | No thrombus or blood stasis (n=214) | Thrombus or blood stasis (n=62) | p value  |
|------------------------|-------------------------------------|---------------------------------|----------|
| Age, yrs               | 65.1±7.6                            | 67.3±7.2                        | 0.043    |
| Female gender          | 61 (28.5%)                          | 25 (40.3%)                      | 0.077    |
| Persistent AF          | 77 (36.0%)                          | 51 (82.3%)                      | <0.001   |
| Comorbidities, n       |                                     |                                 |          |
| CHF                    | 11 (5.1%)                           | 4 (6.5%)                        | 0.751    |
| Hypertension           | 135 (63.1%)                         | 47 (75.8%)                      | 0.063    |
| Age >75 yrs            | 19 (8.9%)                           | 8 (12.9%)                       | 0.348    |
| Diabetes mellitus      | 49 (22.9%)                          | 16 (25.8%)                      | 0.635    |
| Dyslipidemia           | 42 (19.6%)                          | 15 (24.2%)                      | 0.434    |
| Stroke                 | 87 (40.7%)                          | 51 (82.3%)                      | <0.001   |
| CHADS:*                | 1.5±1.0                             | 1.8±0.8                         | 0.006    |
| CHADS:                 | 2.3±1.5                             | 3.4±1.2                         | <0.001   |
| CHA2DS-VASe*           | 1.8±1.2                             | 2.3±1.0                         | 0.004    |
| CHA2DS-VASe            | 2.6±1.7                             | 4.0±1.3                         | <0.001   |
| LVEF, %                | 63.4±8.6                            | 61.9±11.5                      | 0.379    |
| LA volume, cm³         | 141.0±41.4                          | 190.2±52.8                      | <0.001   |
| LAA volume, cm³        | 13.9±6.8                            | 17.1±8.0                        | 0.01     |
| LAA/LA volume, %       | 9.9±3.7                             | 9.1±3.5                         | 0.218    |
| Orifice area, cm²      |                                     |                                 |          |
| LAA                    | 4.9±1.7                             | 6.2±2.5                         | <0.001   |
| LSPV                   | 3.5±1.2                             | 4.1±1.8                         | 0.007    |
| LIPV                   | 2.0±0.8                             | 2.5±1.2                         | 0.003    |
| RSPV                   | 3.8±1.3                             | 3.8±1.6                         | 0.906    |
| RIPV                   | 2.7±1.0                             | 2.9±1.3                         | 0.153    |

AF, atrial fibrillation; CHF, congestive heart failure; LVEF, left ventricular ejection fraction; LA, left atrium; LAA, left atrial appendage; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; RSPV, right superior pulmonary vein; RIPV, right inferior pulmonary vein.

*CHADS: and CHA2DS-VASe scores before stroke for AF with stroke group.

volume (17.1±8.0 cm³ vs. 13.9±6.8 cm³, p=0.01), and the left superior (4.1±1.8 cm² vs. 3.5±1.2 cm², p=0.007) and inferior PV orifices (2.5±1.2 cm² vs. 2.0±0.8 cm², p=0.003) were larger in patients with thrombus or stasis of the LAA. However, the orifice areas of the right superior and inferior PVs showed no differences between two groups.

Multiple logistic regression analysis of risk factors for stroke

Multiple possible clinical predictors and CT measurements were assessed as univariate and multivariate risk factors for stroke (Table 4). The significant univariate risk factors of stroke were hypertension, diabetes mellitus, persistent AF, thrombus or blood stasis on MDCT, higher CHADS: and CHA2DS-VASe score, larger LA volume, and larger LAA, LSPV, and LIPV orifice areas. When adjusted for CHA2DS-VASe score, the orifice areas of the left superior PV (OR 1.55, 95% CI 1.31–1.84, p<0.001), the left inferior PV (OR 2.66, 95% CI 1.96–3.61, p<0.001), and the LAA (OR 1.53, 95% CI 1.35–1.74, p<0.001) were independent risk factors of stroke with LA volume (per 10 cm³, OR 1.16, 95% CI 1.09–1.23, p<0.001) and thrombus or blood stasis seen on MDCT (OR 11.94, 95% CI 5.95–23.98, p<0.001). When the orifice areas were accounted for individual components of CHA2DS-V ASc score and the presence of thrombus or blood stasis on MDCT, ostial areas of left side structures, i.e., LAA, LSPV, and LIPV, were still independent risk factors of stroke but ostial areas of right side structures were not.

In the ROC curve analysis, LAA orifice area, LA volume, LIPV orifice area, and LSPV orifice area predicted stroke in AF patients with area under the curves of 0.739, 0.720, 0.674, and 0.587, respectively (Fig. 3).

DISCUSSION

Major findings

The main finding of this study was significant dilation of the left PVs and the LAA in AF patients with stroke. However, similar findings could not be demonstrated in the right
Our study suggests that prominent anatomic remodeling of the left LA structures may play an important role in the occurrence of stroke in AF patients. To the best of our knowledge, this is the first study to show more prominent structural remodeling of left-side structures such as LAA and left PVs than right PVs in non-valvular AF patients with stroke.

Remodeling of the LA and LAA in AF

It is well known that the relationship between LA chamber enlargement and AF is complex and that structural changes may lead to persistence of arrhythmia. The Framingham heart study showed that the relative risk for the subsequent development of stroke was 2.4 in men and 1.4 in women for every 10-mm increase in LA size. This finding is consistent with the results of this study. Increased LA volume by every 10 cm$^3$ was an independent risk factor of stroke in multivariate logistic analysis (OR 1.09, 95% CI 1.02–1.17, p=0.014).

LAA is an important source of emboli in 70–90% cases of AF. Embryologically, the LAA is a remnant of the primordial LA. The LAA lies anterior to the atrioventricular sulcus and is in close proximity to the left circumflex artery,
the left phrenic nerve, and the left PVs. A study of post-mortem and explanted hearts showed that atrial appendages from patients with atrial fibrillation have three times the volume of those in sinus rhythm. In this study, LAA dilation and enlargement of the LAA orifice were related to a higher risk of stroke. Previously, it was reported that the dilation of the LAA dimensions predict stroke in patients with AF. In our study, the LAA/LA ratio was significantly higher in patient with stroke than other groups (Table 2). Although the volume of both LA and LAA were larger in patient with thrombus/stasis, the ratio of LAA/LA was not significantly different between the two groups. However, previous studies demonstrated that the thrombus was not observed in 20–40% of AF patients with recent thromboembolism.

Recently, Di Biase, et al. reported that patients with Chicken Wing LAA morphology are less likely to have an embolic event, even after controlling for comorbidities and CHADS: score. This result is consistent with our results in that stroke incidence is lower when there is less remodeling of the LAA. However, we could not find a relationship between stroke and LAA morphology.

**Prominent enlargement of left-sided LA structures in patients with stroke**

In the AF group, atrial myocardium in the PVs was characterized by more severe discontinuity, hypertrophy, and fibrosis. However, PV remodeling has not been fully elucidated in AF patients with stroke. Interestingly, the ostia of left-sided PVs were larger in AF patients with stroke than in those without stroke. However, right-sided PVs showed no differences between the AF groups. Kim, et al. reported that the ostia of the left-sided PVs were more elliptical than right-sided PVs. Tsao, et al. investigated the change of PV by magnetic resonance angiography and showed that the diameter of LSPV was progressively enlarged from control group to paroxysmal AF and to chronic AF, but the diameter of RSPV was not significantly different between paroxysmal AF and chronic AF. However, although the superior PVs were larger in those patients with AF, when this was adjusted with the concomitant increase in LA size, this difference was not significant.

In this study, the RSPV and RIPV ostial areas were larger in persistent than paroxysmal AF. However, the RSPV and RIPV ostial areas were not different between patients with and without stroke. This finding might be related with confounding factors such as smaller body mass index and slightly higher proportion of female patients in the stroke group.

**Study limitations**

Our study had several limitations. Although we found an association of increased ostial size of left side PVs and stroke, it is possible that the differences are reflective of inherent anatomical differences rather than structural remodeling. Because this study was performed as a case-control study, we could not show a progressive increase in the orifice areas in the same AF patient group. It would be better if the changes in LAA and PV orifice diameters were evaluated by serial CT scan. Another issue is whether left atrial appendage and left pulmonary vein enlargement is caused by atrial fibrillation or whether it is related to hypertension, diastolic dysfunction, or other cardiovascular diseases that are prevalent in stroke patients. A more detailed, prospective study is needed to address these issues.

**Conclusion**

Compared with right PVs, the left PVs and LAA underwent...
more significant ostial dilatation in patients with AF and stroke than in those with AF only. This finding suggests that remodeling of left-sided LA structures might be related with the occurrence of stroke.

**ACKNOWLEDGEMENTS**

This study was supported in part by research grants of the Basic Science Research Program through the National Research Foundation of Korea, the Ministry of Education, Science and Technology (2012-0007604, 2012-045367), and the Korean Healthcare technology R&D project, Ministry of Health & Welfare (A121668).

**REFERENCES**

1. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989;46:727-43.
2. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
3. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American heart association/american stroke association. Stroke 2011;42:227-76.
4. Jais P, Haïssaguerre M, Shah DC, Chouairi S, Gence L, Hocini M, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997;95:572-6.
5. Haïssaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
6. Teh AW, Kalman JM, Lee G, Medi C, Heck PM, Ling LH, et al. Electroanatomic remodelling of the pulmonary veins associated with age. Europace 2012;14:46-51.
7. Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008;51:1-11.
8. Herweg B, Sichrovsky T, Polosajian L, Rozenshtein A, Steinberg JS. Hypertension and hypertensive heart disease are associated with increased ostial pulmonary vein diameter. J Cardiovasc Electrophysiol 2005;16:2-5.
9. Liu T, Li G. Pulmonary vein dilatation: another possible crosslink between left atrial enlargement and atrial fibrillation? Int J Cardiol 2008;123:193-4.
10. Beinart R, Heist EK, Newell JB, Holmvang G, Ruskin JN, Mansour M. Left atrial appendage dimensions predict the risk of stroke/TIA in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2011;22:10-5.
11. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused Update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-90.
12. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
13. Kim YH, Marom EM, Herndon JE 2nd, McAdams HP. Pulmonary vein diameter, cross-sectional area, and shape: CT analysis. Radiology 2005;235:43-9.
14. Yuan XP, Bach D, Skanes A, Drangova M. Assessment of intra- and interobserver variability of pulmonary vein measurements from CT angiography. Acad Radiol 2004;11:1211-8.
15. Maeda S, Iesaka Y, Otomo K, Uno K, Nagata Y, Suzuki K, et al. No severe pulmonary vein stenosis after extensive encircling pulmonary vein isolation: 12-month follow-up with 3D computed tomography. Heart Vessels 2011;26:440-8.
16. Lemola K, Sneider M, Desjardins B, Case I, Chugh A, Hall B, et al. Effects of left atrial ablation of atrial fibrillation on size of the left atrium and pulmonary veins. Heart Rhythm 2004;1:576-81.
17. Schwartzman D, Lacomis J, Wigginton WG. Characterization of left atrium and distal pulmonary vein morphology using multidimensional computed tomography. J Am Coll Cardiol 2003;41:1349-57.
18. Manghut NE, Mathias HC, Kakani N, Hamilton MC, Morgan-Hughes G, Roobottom CA. Pulmonary venous evaluation using electrocardiogram-gated 64-detector row cardiac CT. Br J Radiol 2012;85:965-71.
19. Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol 2012;60:531-8.
20. Hur J, Kim YJ, Nam JE, Choe KO, Choi EY, Shim CY, et al. Thrombus in the left atrial appendage in stroke patients: detection with cardiac CT angiography--a preliminary report. Radiology 2008;249:81-7.
21. Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995;92:835-41.
22. Black IW, Hopkins AP, Lee LC, Walsh WF. Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in nonanticoagulated patients. Am Heart J 1993;126:375-81.
23. Fuster V, Rydén LE, Cannon DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/ESC focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:e269-367.
24. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition,
Pulmonary Vein Remodeling and Stroke

25. Kim YL, Joung B, On YK, Shim CY, Lee MH, Kim YH, et al. Early experience using a left atrial appendage occlusion device in patients with atrial fibrillation. Yonsei Med J 2012;53:83-90.
26. Wang Y, Di Biase L, Horton RP, Nguyen T, Morhanty P, Natale A. Left atrial appendage studied by computed tomography to help planning for appendage closure device placement. J Cardiovasc Electrophysiol 2010;21:973-82.
27. Douglas YL, Jongbloed MR, Gittenberger-de Groot AC, Evers D, Dion RA, Voigt P, et al. Histology of vascular myocardial wall of left atrial body after pulmonary venous incorporation. Am J Cardiol 2006;97:662-70.
28. Shirani J, Alaeddini J. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. Cardiovasc Pathol 2000;9:95-101.
29. Mansour M, Mandapati R, Berenfeld O, Chen J, Samie FH, Jalife J. Left-to-right gradient of atrial frequencies during acute atrial fibrillation in the isolated sheep heart. Circulation 2001;103:2631-6.
30. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001;32:803-8.
31. Hassink RJ, Aretz HT, Ruskin J, Keane D. Morphology of atrial myocardium in human pulmonary veins: a postmortem analysis in patients with and without atrial fibrillation. J Am Coll Cardiol 2003;42:1108-14.
32. Tsao HM, Yu WC, Cheng HC, Wu MH, Tai CT, Lin WS, et al. Pulmonary vein dilation in patients with atrial fibrillation: detection by magnetic resonance imaging. J Cardiovasc Electrophysiol 2001;12:809-13.
33. Lin WS, Prakash VS, Tai CT, Hsieh MH, Tsai CF, Yu WC, et al. Pulmonary vein morphology in patients with paroxysmal atrial fibrillation initiated by ectopic beats originating from the pulmonary veins: implications for catheter ablation. Circulation 2000;101:1274-81.
34. Kato R, Lickfett L, Meininger G, Dickfeld T, Wu R, Juang G, et al. Pulmonary vein anatomy in patients undergoing catheter ablation of atrial fibrillation: lessons learned by use of magnetic resonance imaging. Circulation 2003;107:2004-10.
### Supplementary Table 1. Comparisons of Pulmonary Vein Ostia According to Type of Atrial Fibrillation (AF)

| Orifice area, cm² | Paroxysmal AF (n=148) | Persistent AF (n=128) | p value |
|------------------|------------------------|------------------------|---------|
| LAA              | 4.5±1.4                | 5.9±2.3                | <0.001  |
| LSPV             | 3.3±1.1                | 4.0±1.5                | <0.001  |
| LIPV             | 1.9±0.7                | 2.3±1.1                | <0.001  |
| RSPV             | 3.7±1.2                | 4.0±1.5                | 0.034   |
| RIPV             | 2.5±0.9                | 3.0±1.2                | <0.001  |
| LA volume, cm³   | 126.6±29.9             | 179.0±49.7             | <0.001  |

LA, left atrium; LAA, left atrial appendage; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; RSPV, right superior pulmonary vein; RIPV, right inferior pulmonary vein.